FDA Probes Possible Cancer Risk Tied to Novartis Zolgensma Therapy
US regulator opens a review of tumor risk in patients given Zolgensma, after Novartis reported nine cases. Details are according to TradingView, citing dpa-AFX and RTTNews.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, the US Food and Drug Administration has opened an investigation into a possible risk of new tumors in patients treated with Novartis' Zolgensma gene therapy. On November 5, Novartis disclosed nine reports of tumors in patients treated since the 2019 approval. In two cases, vector DNA integration involving the GLI1 gene was found.
The regulator concluded that the risk also applies to Itvisma, since both therapies use the same vector and construct, although no tumors have been reported after Itvisma administration so far. The FDA still considers the benefits of both products to outweigh their risks for approved uses, but is assessing whether further steps, including label changes, are needed.
why it matters
For Novartis, this is a potential blow to the Zolgensma Group, which posted sales of $1.071 billion in the first nine months of 2026, up from $925 million a year earlier. NVS closed Friday at $162.55, up 0.38%. The outcome of the review could shape investor views of the entire AAV-based gene therapy segment.
market impact
Novartis: possible restrictions on Zolgensma and Itvisma weigh on the company's shares
- Novartis (NVS) pressure down — risk of regulatory restrictions and reputational damage to AAV-based therapies
tags
instruments
sources
- FDA Investigates Cancer Risk Associated With Novartis' Zolgensma Gene Therapy — TradingView, 7 November 2026 at 12:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗